24Dec 2022
Ninety‐day mortality following transoral robotic surgery or radiation at Commission on Cancer‐accredited facilities

Ninety‐day mortality following transoral robotic surgery or radiation at Commission on Cancer‐accredited facilities

Postoperative mortality for oropharynx squamous cell carcinoma (OPSCC) with transoral robotic surgery (TORS) varies from 0.2% to 6.5% in trials; the real‐world rate is unknown. 3639 patients were treated with TORS and 1937 with radiotherapy. There is minimal difference between 90‐day mortality in patients treated with TORS or radiotherapy for early‐stage OPSCC. While overall rates are low, for patients with an expectation of cure, work is needed to identify optimal treatment.

  • #ent

Like

Save

Share